BioSpace News Archive

TScan Therapeutics, Inc. (Nasdaq: TCRX) today announced that the Company will be presenting a Trial in Progress (TIP) poster at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

LAVATherapeutics N.V. (Nasdaq:LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its unique Gammabody™ platform, which involves the development of bispecific gamma-delta T cell engagers.

CooperCompanies announced financial results for its fiscal second quarter ended April 30, 2023.

Immunocore Holdings Plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, announced that management will present at the following investor conferences in June:

Amarin Corporation plc announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that management will be participating in the following investor conferences:

Medtronic plc announced that Ken Washington, Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of May 31, 2023, grants of a non-qualified stock option award to purchase 15,600 shares of its common stock and restricted stock units covering 7,800 shares of its common stock under the Inducement Plan to one new employee.

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma.